It has been my thinking that the addition of NNZ-2591 to the portfolio would add some degree of complexity to a potential deal or take over offer. It is some way away from any meaningful trial that could add any value to the shareprice. However Trofinetide is well in progress.
I can't see Neuren negotiating anything without consideration of NNZ-2591 (which is still in a premature phase).
I can understand long term holders frustration, but I don't see any clear path presenting itself well into next year (end of June latest?) once phase 3 concludes. There will be some time after that before results are available for review. How NNZ-2591 plays out in the meantime is anyones guess.
NEU Price at posting:
$2.00 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)